← Back to Home

Lorundrostat sustains blood pressure reduction for 48 weeks, adding long-term data ahead of FDA review

For patients whose blood pressure remains difficult to control despite taking multiple medications, sustained efficacy is critical. The latest extension trial shows that more than half of participants achieved systolic blood pressure below 130 mmHg, but the open-label design and risk of hyperkalemia also define the weight of this evidence.

By SURL BioNews

For people whose blood pressure remains above target despite taking multiple antihypertensive medications, the test of a new drug is not just how much it lowers blood pressure initially, but whether that effect lasts. On November 8, Mineralys Therapeutics announced long-term follow-up results for lorundrostat: among the 504 participants included in the efficacy analysis, mean systolic blood pressure at week 48 was 17.8 mmHg lower than the original baseline, adding evidence of sustained efficacy for the drug, which remains under review.

These data from the Transform-HTN extension trial were presented at the 2026 American Heart Association Scientific Sessions. Barts Health NHS Trust, which served as the lead UK trial center, also confirmed that participants continued taking lorundrostat in addition to their existing antihypertensive medications; at 48 weeks, 56% of participants had systolic blood pressure below 130 mmHg as measured by automated office blood pressure assessment. Global principal investigator Manish Saxena presented the findings in Chicago.

Lorundrostat is a once-daily oral aldosterone synthase inhibitor that reduces aldosterone production by inhibiting CYP11B2. This study focused on patients with inadequately controlled or resistant hypertension, evaluating whether this mechanism could provide longer-term blood pressure control on top of existing treatment.

Understanding the starting point of the “48 weeks” is particularly important. The population covered by this announcement first received 12 weeks of treatment in the Launch-HTN trial, followed by a 36-week open-label extension; the 17.8 mmHg reduction was measured against blood pressure at the start of Launch-HTN, rather than representing an additional reduction during the extension. The extension study enrolled 632 participants in total. The efficacy analysis excluded those assigned to placebo in a short-term randomized withdrawal substudy, leaving 504 participants.

The longer follow-up also clarified the safety profile. The company said there were no new clinically important safety findings compared with Launch-HTN; however, 32 of the 632 participants, approximately 5.1%, required a dose reduction, interruption or discontinuation of the study drug because of hyperkalemia, including 10 who discontinued treatment because of hyperkalemia. Increases in blood potassium and decreases in estimated glomerular filtration rate also occurred early in treatment, then remained stable through week 48.

These results primarily address whether efficacy can be sustained, and their interpretation must still account for the limits of the study design. The open-label extension had no ongoing blinded placebo control, and participants were drawn from people in the previous trial who were eligible and willing to continue treatment. The full reduction therefore cannot be directly interpreted as the drug’s effect relative to placebo, nor can these findings support a claim that the drug has been proven to reduce myocardial infarction, stroke or worsening kidney disease.

According to Mineralys’ announcement, the FDA is reviewing the application for lorundrostat in combination with other antihypertensive medications, with a target review date of December 22, 2026; this is a review timeline and does not guarantee approval. For this investigational therapy, nearly a year of blood pressure data adds support for continued use, while changes in blood potassium and kidney function remain important considerations in assessing long-term benefits and risks.

References

  1. Mineralys Therapeutics
  2. Barts Health NHS Trust